Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Executive Summary
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.
You may also be interested in...
Keeping Track: Aimmune’s Peanut Allergen Approved; Novartis’ Inclisiran, Pfizer/Lilly’s Tanezumab, Bayer’s Nifurtimox Submitted
Highlights of the latest drug development news from our US FDA Performance Tracker.
Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.
Lilly Has A Couple Of Controversies To Cover During Earnings Call
Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30.